2024
Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails
Springer S. Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails. JAMA Network Open 2024, 7: e2434649. PMID: 39316405, DOI: 10.1001/jamanetworkopen.2024.34649.Peer-Reviewed Original ResearchSerious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder
Springer S. Serious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder. JAMA Network Open 2024, 7: e2421640. PMID: 39046746, DOI: 10.1001/jamanetworkopen.2024.21640.Peer-Reviewed Original Research
2020
Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIV
2019
Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations
Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.Peer-Reviewed Original ResearchConceptsViral loadART adherenceAdherence measuresSelf-reported antiretroviral therapy (ART) adherenceCriminal justice-involved populationsSelf-reported ART adherenceLogistic regressionSelf-reported health statusContinuum of HIVDetectable viral loadPlasma viral loadAIDS Research NetworkAntiretroviral therapy adherenceAssociation of adherenceHealth status levelsVisual analog scaleViral load dataMixed-effects logistic regressionMixed effects linear regressionEffects linear regressionJustice-involved populationsEffects logistic regressionVL outcomesCD4 countART dosesTreating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testing
2018
Brief Report
Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 283-287. PMID: 30036277, PMCID: PMC6681811, DOI: 10.1097/qai.0000000000001803.Peer-Reviewed Original ResearchConceptsPHQ-9 scoresDepressive symptomsSubstance useATS useLower oddsMean decreaseAmphetamine-type substancesAIDS Research NetworkCocaine/crack useDepressive symptom scoresMental health disordersJoint longitudinal-survival modelCocaine/crackPoor outcomeSymptom scoresPHQ-9Health disordersIllicit opiatesSymptomsPLWHLongitudinal assessmentSite cohortSubstance use frequencyCrack useAbstinenceApproaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations
Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug And Alcohol Dependence 2018, 194: 59-68. PMID: 30412898, PMCID: PMC6312501, DOI: 10.1016/j.drugalcdep.2018.10.003.Peer-Reviewed Original ResearchExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesPrevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision
Mbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, Springer SA. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. Substance Use & Misuse 2018, 53: 1519-1528. PMID: 29333954, PMCID: PMC6432769, DOI: 10.1080/10826084.2017.1416400.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-9Mood disordersBipolar disorderOpioid usersAddiction Severity Index-LiteOpioid use treatmentCriminal justice supervisionOpioid-dependent individualsSelf-reported mood disordersOpioid-dependent populationsComprehensive psychiatric careAdverse health consequencesLarger parent studyLifetime suicide attemptsHigh rateQuestionnaire-9Positive screenJustice-involved individualsSevere depressionTreatment utilizationGeneral U.S.Psychiatric careControl trialParent studyPsychiatric disorders
2017
Cohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort membersExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexoneGender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium
Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS And Behavior 2017, 21: 2945-2957. PMID: 28188460, PMCID: PMC5552433, DOI: 10.1007/s10461-017-1722-9.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsRisk behaviorsHIV risk reduction interventionsHIV-negative participantsHIV-positive womenHIV-positive menMultilevel mixed-effects logistic regression modelSero-discordant partnersMixed effects logistic regression modelsCondomless sexual intercourseRisk reduction interventionsLogistic regression modelsCJ populationsBehavior Assessment ToolHIV transmissionCriminal justice populationsHigher oddsHIVReduction interventionsSexual intercourseLarge-scale studiesBaseline dataInjection equipmentJustice populationsAssessment tool
2016
Co-calibration of two self-reported measures of adherence to antiretroviral therapy
Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2016, 29: 464-468. PMID: 27910703, PMCID: PMC5291764, DOI: 10.1080/09540121.2016.1263721.Peer-Reviewed Original ResearchConceptsVisual analog scaleAntiretroviral therapyAdherence measuresAIDS Clinical Trials Group questionnaireHigh-risk vulnerable populationsVulnerable populationsCare cohortAnalog scaleVAS scaleHIV StudyAdherence dataClinical successConsortium studyGroup questionnaireTherapyDosesSelf-report measuresAdherence
2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic featuresPrevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study
Lincoln T, Simon-Levine D, Smith J, Donenberg GR, Springer SA, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. Journal Of Correctional Health Care 2015, 21: 125-139. PMID: 25788608, PMCID: PMC4433291, DOI: 10.1177/1078345815574566.Peer-Reviewed Original ResearchConceptsEmotional distressJail detaineesSeverity Index scoreAddiction Severity Index (ASI) scoresPoor physical healthMental health assessmentHIV/AIDSEmotional distress scoresObservational studyIndex scoreDistress scoresHealth servicesHealth RankingsSubstance abusePhysical healthJail systemHealth assessmentBisexual orientationSpecific correlatesDistressFamily supportPrevalenceScoresHigh levelsPLWHAValidation of a Brief Measure of Opioid Dependence
Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence. Journal Of Correctional Health Care 2015, 21: 12-26. PMID: 25559628, PMCID: PMC4435561, DOI: 10.1177/1078345814557513.Peer-Reviewed Original ResearchConceptsOpioid dependencePredictive valueMini International Neuropsychiatric InterviewModerate diagnostic agreementHIV-positive individualsInternational Neuropsychiatric InterviewNegative predictive valuePositive predictive valueAverage administrationNeuropsychiatric InterviewInter-item correlationsMental disordersDiagnostic agreementStatistical ManualStrong internal consistencyComprehensive interviewPrimary measureFourth EditionInternal consistencyPsychometric propertiesResearch settingsBrief measureConcordance analysisInitial validationAdministration
2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone
2013
Partner violence and health among HIV-infected jail detainees
Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prisoner Health 2013, 9: 124-141. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/ijph-03-2013-0011.Peer-Reviewed Original ResearchConceptsIntimate partner violenceSubstance use disordersHIV treatment outcomesHealthcare utilizationPartner violenceTreatment outcomesJail detaineesIPV exposureEffects of IPVHIV secondary preventionPost-release interventionsUntreated mental disordersDepth qualitative interviewsLifetime IPV exposureForms of childhoodHigher alcohol use severityCriminal justice populationsAlcohol use severityViolence reductionCJ populationsTime of incarcerationHIV diagnosisSecondary preventionAdulthood abuseQualitative interviewsContribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severity
2012
Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study
Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS And Behavior 2012, 17: 171-180. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior, AddictiveFemaleHealth Services AccessibilityHealth Services Needs and DemandHIV InfectionsHumansIll-Housed PersonsInsurance, HealthMaleMiddle AgedMultivariate AnalysisPatient DischargePrevalencePrisonsProspective StudiesSeverity of Illness IndexSocial WorkSocioeconomic FactorsSubstance-Related DisordersTreatment OutcomeYoung AdultConceptsOpioid useJail detaineesPoor health outcomesSubstance use disordersSubstance abuse outcomesSubsequent drug useSubstance abuse treatmentOpioid relapseProspective cohortPsychiatric morbidityAppropriate diagnosisHigh prevalenceComplicate treatmentPsychiatric careUse disordersAlcohol severitySix monthsHealth outcomesDrug useHIVHealthcare accessAbuse treatmentSubstance abuseDrug relapseHealthcare outcomes